View Item 

Show simple item record

Doubleâ blind, randomized phase 3 trial of lowâ dose 13â cis retinoic acid in the prevention of second primaries in head and neck cancer: Longâ term followâ up of a trial of the Eastern Cooperative Oncology Groupâ ACRIN Cancer Research Group (C0590)
dc.contributor.authorBhatia, Aarti K.
dc.contributor.authorLee, Ju‐whei
dc.contributor.authorPinto, Harlan A.
dc.contributor.authorJacobs, Charlotte D.
dc.contributor.authorLimburg, Paul J.
dc.contributor.authorRubin, Philip
dc.contributor.authorArusell, Robert M.
dc.contributor.authorDunphy, Eamonn P.
dc.contributor.authorKhandekar, Janardan D.
dc.contributor.authorReiner, Seth A.
dc.contributor.authorBaez‐diaz, Luis
dc.contributor.authorCelano, Paul
dc.contributor.authorLi, Shuli
dc.contributor.authorLi, Yi
dc.contributor.authorBurtness, Barbara A.
dc.contributor.authorAdams, George L.
dc.contributor.authorPandya, Kishan J.
dc.date.accessioned2017-12-15T16:46:40Z
dc.date.available2019-02-01T19:56:25Zen
dc.date.issued2017-12-01
dc.identifier.citationBhatia, Aarti K.; Lee, Ju‐whei ; Pinto, Harlan A.; Jacobs, Charlotte D.; Limburg, Paul J.; Rubin, Philip; Arusell, Robert M.; Dunphy, Eamonn P.; Khandekar, Janardan D.; Reiner, Seth A.; Baez‐diaz, Luis ; Celano, Paul; Li, Shuli; Li, Yi; Burtness, Barbara A.; Adams, George L.; Pandya, Kishan J. (2017). "Doubleâ blind, randomized phase 3 trial of lowâ dose 13â cis retinoic acid in the prevention of second primaries in head and neck cancer: Longâ term followâ up of a trial of the Eastern Cooperative Oncology Groupâ ACRIN Cancer Research Group (C0590)." Cancer 123(23): 4653-4662.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/139904
dc.publisherWiley Periodicals, Inc.
dc.subject.otherchemoprevention
dc.subject.othersecond primary cancer
dc.subject.otherrandomized controlled trial
dc.subject.otheroral cancer
dc.subject.otherhead and neck cancer
dc.titleDoubleâ blind, randomized phase 3 trial of lowâ dose 13â cis retinoic acid in the prevention of second primaries in head and neck cancer: Longâ term followâ up of a trial of the Eastern Cooperative Oncology Groupâ ACRIN Cancer Research Group (C0590)
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139904/1/cncr30920.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139904/2/cncr30920_am.pdf
dc.identifier.doi10.1002/cncr.30920
dc.identifier.sourceCancer
dc.identifier.citedreferenceSiegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: 7 â 30.
dc.identifier.citedreferenceMorris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: subsiteâ specific trends in the era of human papillomavirusâ associated oropharyngeal cancer. J Clin Oncol. 2011; 29: 739 â 746.
dc.identifier.citedreferenceChuang SC, Scelo G, Tonita JM, et al. Risk of second primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries. Int J Cancer. 2008; 123: 2390 â 2396.
dc.identifier.citedreferenceWilliam WN Jr, Papadimitrakopoulou V, Lee JJ, et al. Erlotinib and the risk of oral cancer: the Erlotinib Prevention of Oral Cancer (EPOC) randomized clinical trial. JAMA Oncol. 2016; 2: 209 â 216.
dc.identifier.citedreferenceCancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517: 576 â 582.
dc.identifier.citedreferenceShin DM, Khuri FR, Murphy B, et al. Combined interferonâ alfa, 13â cisâ retinoic acid, and alphaâ tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol. 2001; 19: 3010 â 3017.
dc.identifier.citedreferenceSeixasâ Silva JA Jr, Richards T, Khuri FR, et al. Phase 2 bioadjuvant study of interferon alfaâ 2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: longâ term followâ up. Arch Otolaryngol Head Neck Surg. 2005; 131: 304 â 307.
dc.identifier.citedreferencevan Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H. EUROSCAN, a randomized trial of vitamin A and Nâ acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst. 2000; 92: 977 â 986.
dc.identifier.citedreferenceFine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496 â 509.
dc.identifier.citedreferenceCox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972; 34: 187 â 220.
dc.identifier.citedreferencePeto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A. 1972; 135: 185 â 207.
dc.identifier.citedreferenceKaplan EL Meier P. Nonparametric assessment of incomplete observations. J Am Stat Assoc. 1958; 53: 457 â 481.
dc.identifier.citedreferenceGray RJ. A class of Kâ sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141 â 1154.
dc.identifier.citedreferenceBerkson J, Gage RP. Calculation of survival rates for cancer. Proc Staff Meet Mayo Clin. 1950; 25: 270 â 286.
dc.identifier.citedreferenceKhuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of lowâ dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006; 98: 441 â 450.
dc.identifier.citedreferenceBolla M, Lefur R, Ton Van J, et al. Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric doubleâ blind randomised study. Eur J Cancer. 1994; 30A: 767 â 772.
dc.identifier.citedreferenceBenner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: longâ term followâ up. J Natl Cancer Inst. 1994; 86: 140 â 141.
dc.identifier.citedreferenceHong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamousâ cell carcinoma of the head and neck. N Engl J Med. 1990; 323: 795 â 801.
dc.identifier.citedreferenceHong WK, Endicott J, Itri LM, et al. 13â cisâ retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986; 315: 1501 â 1505.
dc.identifier.citedreferenceSporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 1976; 35: 1332 â 1338.
dc.identifier.citedreferenceVikram B. Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol. 1984; 110: 564 â 565.
dc.identifier.citedreferenceLicciardello JT, Spitz MR, Hong WK. Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radiat Oncol Biol Phys. 1989; 17: 467 â 476.
dc.identifier.citedreferenceCooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys. 1989; 17: 449 â 456.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr30920.pdf
Size:
390.4KB
Format:
PDF
View/Open
Name:
cncr30920_am.pdf
Size:
977.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.